| SUMO-3 promotes the ubiquitin-dependent turnover of TRIM55. | SUMO-3 promotes the ubiquitin-dependent turnover of TRIM55.
Hammami NEH, Mérindol N, Plourde MB, Maisonnet T, Lebel S, Berthoux L. | 02/2/2024 |
| SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307. | SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.
Feng D, He J, Yuan M, Chen Q, Zeng X, Zhou Q, Wu J, Han B. | 12/26/2023 |
| NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation. | NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation.
Hu Y, Chen C, Tong X, Chen S, Hu X, Pan B, Sun X, Chen Z, Shi X, Hu Y, Shen X, Xue X, Lu M., Free PMC Article | 01/29/2022 |
| SUMO paralogue-specific functions revealed through systematic analysis of human knockout cell lines and gene expression data. | SUMO paralogue-specific functions revealed through systematic analysis of human knockout cell lines and gene expression data.
Bouchard D, Wang W, Yang WC, He S, Garcia A, Matunis MJ., Free PMC Article | 01/29/2022 |
| Opposing biological functions of the cytoplasm and nucleus DAXX modified by SUMO-2/3 in gastric cancer. | Opposing biological functions of the cytoplasm and nucleus DAXX modified by SUMO-2/3 in gastric cancer.
Chen C, Sun X, Xie W, Chen S, Hu Y, Xing D, Xu J, Chen X, Zhao Z, Han Z, Xue X, Shen X, Lin K., Free PMC Article | 03/27/2021 |
| Small ubiquitin-related modifier (SUMO) 3 and SUMO4 gene polymorphisms in Parkinson's disease. | Small ubiquitin-related modifier (SUMO) 3 and SUMO4 gene polymorphisms in Parkinson's disease.
Küçükali CI, Salman B, Yüceer H, Ulusoy C, Abacı N, Ekmekci SS, Tüzün E, Bilgiç B, Hanağası HA. | 03/20/2021 |
| RNF4-mediated SUMO-targeted ubiquitination relieves PARIS/ZNF746-mediated transcriptional repression. | RNF4-mediated SUMO-targeted ubiquitination relieves PARIS/ZNF746-mediated transcriptional repression.
Nishida T, Yamada Y. | 11/28/2020 |
| The SUMO3 modification of PIAS1 modulates AR cellular distribution and stability. | SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability.
Yang N, Liu S, Qin T, Liu X, Watanabe N, Mayo KH, Li J, Li X., Free PMC Article | 10/3/2020 |
| Formation of SUMO3-conjugated chains of MAVS induced by poly(dA:dT), a ligand of RIG-I, enhances the aggregation of MAVS that drives the secretion of interferon-beta in human keratinocytes. | Formation of SUMO3-conjugated chains of MAVS induced by poly(dA:dT), a ligand of RIG-I, enhances the aggregation of MAVS that drives the secretion of interferon-β in human keratinocytes.
Choi GW, Lee Y, Yun M, Kang J, Lee SB. | 09/5/2020 |
| Study demonstrated for the first time that PKA stimulated OAT3 expression and transport activity by altering the trafficking kinetics of OAT3 possibly through the crosstalk between SUMOylation and ubiquitination. OAT3 is subjected to post-translational modification by SUMO-2 and SUMO-3 not by SUMO-1. | Activation of Protein Kinase A Stimulates SUMOylation, Expression, and Transport Activity of Organic Anion Transporter 3.
Wang H, Zhang J, You G., Free PMC Article | 02/15/2020 |
| SUMO-regulated signaling pathways contribute at many distinct levels to the cellular response to low oxygen. | Hypoxia-induced Changes in SUMO Conjugation Affect Transcriptional Regulation Under Low Oxygen.
Chachami G, Stankovic-Valentin N, Karagiota A, Basagianni A, Plessmann U, Urlaub H, Melchior F, Simos G., Free PMC Article | 01/25/2020 |
| different SUMO paralogues determine the fates of wild type and mutant CFTRs. | Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation.
Gong X, Liao Y, Ahner A, Larsen MB, Wang X, Bertrand CA, Frizzell RA., Free PMC Article | 06/29/2019 |
| Data suggest that ATF5 is modified by SUMO2/3 at a conserved SUMO-targeting consensus site; this SUMOylation of ATF5 appears to be required for transport of ATF5 to centrosome. (ATF5 = activating transcription factor-5; SUMO = small ubiquitin-like modifier) | SUMO2/3 modification of activating transcription factor 5 (ATF5) controls its dynamic translocation at the centrosome.
Yuan Y, Gaither K, Kim E, Liu E, Hu M, Lengel K, Qian D, Xu Y, Wang B, Knipprath H, Liu DX., Free PMC Article | 12/22/2018 |
| SUMO3 abrogates PKR activation upon poly(I:C) transfection or viral infection. | Differential effects of SUMO1 and SUMO3 on PKR activation and stability.
Maarifi G, El Asmi F, Maroui MA, Dianoux L, Chelbi-Alix MK., Free PMC Article | 12/22/2018 |
| The hSUMO3 was cleaved from hrVEGF-A121 with SUMO protease. | Soluble Production of Human Recombinant VEGF-A121 by Using SUMO Fusion Technology in Escherichia coli.
Samuel RVM, Farrukh SY, Rehmat S, Hanif MU, Ahmed SS, Musharraf SG, Durrani FG, Saleem M, Gul R. | 10/27/2018 |
| conclude that SUMO3-tagged hBMP2 is more suited for generation of soluble form of the protein and addition of SUMO3 tag does not affect the functional activity of hBMP2 | Small Ubiquitin-Like Modifier Protein 3 Enhances the Solubilization of Human Bone Morphogenetic Protein 2 in E. coli.
Hanif MU, Yaseen A, Gul R, Mirza MU, Nawaz MH, Ahmed SS, Aziz S, Chaudhary S, Khan AA, Shoaib M. | 09/29/2018 |
| findings demonstrate that SUMO2 and SUMO3 are specific and essential negative regulators of a noncanonical mechanism of IFN induction. | SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response.
Crowl JT, Stetson DB., Free PMC Article | 09/8/2018 |
| Increased protein level of HSP27 through SUMO2/3-mediated SUMOylation plays crucial roles in the progression of primary hepatocellular carcinoma. | SUMOylation of HSP27 by small ubiquitin-like modifier 2/3 promotes proliferation and invasion of hepatocellular carcinoma cells.
Ge H, Du J, Xu J, Meng X, Tian J, Yang J, Liang H., Free PMC Article | 06/16/2018 |
| Increased post-translational modification of proteins by SUMO-2/3 is a cytoprotective response against cell stress induced by ischaemia and reperfusion. | Increased SUMO-2/3-ylation mediated by SENP3 degradation is protective against cadmium-induced caspase 3-dependent cytotoxicity.
Luo J, Gurung S, Lee L, Henley JM, Wilkinson KA, Guo C. | 10/7/2017 |
| Data suggest that PIASy exhibits a SIM (SUMO-interacting motif) in addition to the SIM identified in homologous proteins in other species; both SIMs are located near C terminus of PIASy, and both are required for full ligase activity of PIASy; hydrophobic core residues of the new SIM are essential in binding to SUMO-3. (PIASy = protein inhibitors of activated STAT y; SUMO-3 = small ubiquitin-like modifier 3) | Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K, Park H, Pandey N, Azuma Y, De Guzman RN., Free PMC Article | 07/8/2017 |
| The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1gamma sumoylation and poly-SUMO chain elongation. | The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1γ sumoylation and poly-SUMO chain elongation.
Sohn SY, Hearing P., Free PMC Article | 01/28/2017 |
| FOXP2 can be modified with all three human SUMO proteins and that PIAS1 promotes this process. | The language-related transcription factor FOXP2 is post-translationally modified with small ubiquitin-like modifiers.
Estruch SB, Graham SA, Deriziotis P, Fisher SE., Free PMC Article | 12/31/2016 |
| Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma. | Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma.
Liu J, Sha M, Wang Q, Ma Y, Geng X, Gao Y, Feng L, Shen Y, Shen Y., Free PMC Article | 07/2/2016 |
| Data indicate that small ubiquitin-like modifiers SUMO1, SUMO2, or SUMO3 were found in nuclear speckles. | Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G, Maroui MA, Dutrieux J, Dianoux L, Nisole S, Chelbi-Alix MK. | 12/19/2015 |
| Adenovirus E4-ORF3 targets PIAS3 and together with E1B-55K remodels SUMO2/SUMO3 Interactions in the nucleus and at virus genome replication domains. | Adenovirus E4-ORF3 Targets PIAS3 and Together with E1B-55K Remodels SUMO Interactions in the Nucleus and at Virus Genome Replication Domains.
Higginbotham JM, O'Shea CC., Free PMC Article | 12/19/2015 |